Novel Diabetes Treatment
- Summary
- Researchers at Purdue University in collaboration with Oklahoma Medical Research Foundation have developed and assayed a series of lead compounds that act as memapsin 1 inhibitors and increase pancreatic beta cell mass. Treatment with these compounds may also be complimented by other therapeutics that increase insulin production, improve glucose homeostasis, or inhibit hyperglucagonemia.
- Technology Benefits
- Improved glucose homeostasisSpecific enzyme pathway regulation
- Technology Application
- Medical/HealthcarePharmaceuticals
- Detailed Technology Description
- Arun GhoshGhosh GroupPurdue Chemistry
- Countries
- United States
- Application No.
- None
- *Abstract
-
- *Background
- Diabetes is a widely prevalent disease that currently affects 25.8 million people in the United States. The predominant form of diabetes is characterized by hyperglycemia resulting from a combination of reduction in pancreatic beta cell activity and mass, which leads to insufficient insulin production. An enzyme called memapsin 1 is known to be part of the biochemical pathway that leads to the problems with pancreatic beta cells and ultimately causes insulin deficiency. Memapsin 1 deactivates a transmembrane protein shown to increase beta cell proliferation and improve glucose stimulated insulin secretion. The transmembrane protein is deactivated when it undergoes ectodomain cleavage in a process triggered by memapsin 1.
- *IP Issue Date
- None
- *IP Type
- Utility
- *Stage of Development
- Process Validation in Lab
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry
- Country/Region
- USA
For more information, please click Here
